Successful treatment of cancer-associated retinopathy with alemtuzumab.
We herein report a patient with cancer-associated retinopathy who experienced multiple bouts of paraneoplastic retinopathy and optic neuropathy but responded to treatments with alemtuzumab and was able to maintain useful vision over the course of 8 years of follow-up.
Espandar
Ladan
L
Section of Ophthalmology, Unit 441, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
O'Brien
Susan
S
Thirkill
Charles
C
Lubecki
Linda A
LA
Esmaeli
Bita
B
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004596:Electroretinography; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D009901:Optic Nerve Diseases / Q000188:drug therapy* / Q000209:etiology; D010257:Paraneoplastic Syndromes / Q000188:drug therapy*; D012074:Remission Induction; D012164:Retinal Diseases / Q000188:drug therapy* / Q000209:etiology; D014794:Visual Fields
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab